OBJECTIVE: To evaluate impact of the program after up to 6 years of follow-up in survival, virologic, and immunologic response. METHODS: Prospective follow-up of patients initiating first highly active antiretroviral therapy from 2001 to 2007. Chile began in 2001 an expanded access program to antiretroviral therapy. The Chilean AIDS Cohort has enrolled >85% of patients from this program in the public health system. STATISTICAL ANALYSIS: χ², Fisher tests, survival, univariate and multivariate analysis. RESULTS: Five thousand one hundred fifteen adults (16% women); median follow-up: 3.64 years (18,159 patient-years). At baseline: median age, 35.8 years; 45.6% had clinical AIDS; median CD4 cell count, 102 cells per cubic millimeter. Global mortality, 9.0%; loss to follow-up, 6.8%. Probability of survival at 1 and 5 years were 0.95 and 0.89, respectively. First regimen was maintained in 72% of those alive and in control at 1 year and 48% at end of study. Main reason for therapy change/discontinuation was drug toxicity (44.9%). At last visit, 74% of active patients had viral suppression, and median CD4 cell count had reached 301 cells per cubic millimeter. CONCLUSIONS: In this middle-income country, wide access highly active antiretroviral therapy has been successfully implemented and evaluated. Despite advanced disease at initiation, survival, clinical, virologic, and immunologic outcomes have been comparable with that of industrialized countries.
OBJECTIVE: To evaluate impact of the program after up to 6 years of follow-up in survival, virologic, and immunologic response. METHODS: Prospective follow-up of patients initiating first highly active antiretroviral therapy from 2001 to 2007. Chile began in 2001 an expanded access program to antiretroviral therapy. The Chilean AIDS Cohort has enrolled >85% of patients from this program in the public health system. STATISTICAL ANALYSIS: χ², Fisher tests, survival, univariate and multivariate analysis. RESULTS: Five thousand one hundred fifteen adults (16% women); median follow-up: 3.64 years (18,159 patient-years). At baseline: median age, 35.8 years; 45.6% had clinical AIDS; median CD4 cell count, 102 cells per cubic millimeter. Global mortality, 9.0%; loss to follow-up, 6.8%. Probability of survival at 1 and 5 years were 0.95 and 0.89, respectively. First regimen was maintained in 72% of those alive and in control at 1 year and 48% at end of study. Main reason for therapy change/discontinuation was drug toxicity (44.9%). At last visit, 74% of active patients had viral suppression, and median CD4 cell count had reached 301 cells per cubic millimeter. CONCLUSIONS: In this middle-income country, wide access highly active antiretroviral therapy has been successfully implemented and evaluated. Despite advanced disease at initiation, survival, clinical, virologic, and immunologic outcomes have been comparable with that of industrialized countries.
Authors: Serena P Koenig; Luis A Rodriguez; Courtenay Bartholomew; Alison Edwards; Tracie E Carmichael; Geoffrey Barrow; André Cabié; Robert Hunter; Giselle Vasquez-Mora; Avion Quava-Jones; Nicholas Adomakoh; J Peter Figueroa; Bernard Liautaud; Magaly Torres; Jean W Pape Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: Gabriela Carriquiry; Valeria Fink; John Robert Koethe; Mark Joseph Giganti; Karu Jayathilake; Meridith Blevins; Pedro Cahn; Beatriz Grinsztejn; Marcelo Wolff; Jean William Pape; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Catherine Carey McGowan; Bryan Earl Shepherd Journal: J Int AIDS Soc Date: 2015-07-10 Impact factor: 5.396
Authors: Paula M Luz; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramírez; Yanink Caro-Vega; Daniel Hoces; Peter F Rebeiro; Meridith Blevins; Jean W Pape; Claudia P Cortes; Denis Padgett; Pedro Cahn; Valdilea G Veloso; Catherine C McGowan; Beatriz Grinsztejn; Bryan E Shepherd Journal: Open Forum Infect Dis Date: 2015-06-05 Impact factor: 3.835
Authors: Sarah W Beckham; Chris Beyrer; Peter Luckow; Meg Doherty; Eyerusalem K Negussie; Stefan D Baral Journal: J Int AIDS Soc Date: 2016-11-08 Impact factor: 5.396
Authors: Pablo Ferrer; Luisa Montecinos; Mario Tello; Rocio Tordecilla; Consuelo Rodríguez; Marcela Ferrés; Carlos M Pérez; Carlos Beltrán; Maria A Guzmán; Alejandro Afani Journal: Virol J Date: 2013-10-28 Impact factor: 4.099
Authors: Carina Cesar; John R Koethe; Mark J Giganti; Peter Rebeiro; Keri N Althoff; Sonia Napravnik; Angel Mayor; Beatriz Grinsztejn; Marcelo Wolff; Denis Padgett; Juan Sierra-Madero; Eduardo Gotuzzo; Timothy R Sterling; James Willig; Julie Levison; Mari Kitahata; Maria C Rodriguez-Barradas; Richard D Moore; Catherine McGowan; Bryan E Shepherd; Pedro Cahn Journal: J Int AIDS Soc Date: 2016-03-18 Impact factor: 5.396